ATE417600T1 - Pharmazeutische zusammensetzungen mit midazolam in hoher konzentration - Google Patents

Pharmazeutische zusammensetzungen mit midazolam in hoher konzentration

Info

Publication number
ATE417600T1
ATE417600T1 AT05701515T AT05701515T ATE417600T1 AT E417600 T1 ATE417600 T1 AT E417600T1 AT 05701515 T AT05701515 T AT 05701515T AT 05701515 T AT05701515 T AT 05701515T AT E417600 T1 ATE417600 T1 AT E417600T1
Authority
AT
Austria
Prior art keywords
midazolam
pharmaceutical compositions
high concentration
compositions containing
containing high
Prior art date
Application number
AT05701515T
Other languages
English (en)
Inventor
Franciscus Wilhelmus Henricus Merkus
Original Assignee
Merkus Franciscus Wilhelmus He
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merkus Franciscus Wilhelmus He filed Critical Merkus Franciscus Wilhelmus He
Application granted granted Critical
Publication of ATE417600T1 publication Critical patent/ATE417600T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05701515T 2004-01-14 2005-01-13 Pharmazeutische zusammensetzungen mit midazolam in hoher konzentration ATE417600T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0400804.1A GB0400804D0 (en) 2004-01-14 2004-01-14 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE417600T1 true ATE417600T1 (de) 2009-01-15

Family

ID=31726180

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05701515T ATE417600T1 (de) 2004-01-14 2005-01-13 Pharmazeutische zusammensetzungen mit midazolam in hoher konzentration

Country Status (23)

Country Link
US (2) US7700588B2 (de)
EP (1) EP1703896B1 (de)
JP (1) JP5085138B2 (de)
KR (1) KR20060130175A (de)
CN (1) CN1929816B (de)
AT (1) ATE417600T1 (de)
AU (1) AU2005205072B2 (de)
BR (1) BRPI0506868A (de)
CA (1) CA2553890C (de)
DE (1) DE602005011753D1 (de)
DK (1) DK1703896T3 (de)
EA (1) EA014096B1 (de)
ES (1) ES2319667T3 (de)
FI (2) FIC20230023I1 (de)
GB (1) GB0400804D0 (de)
IL (1) IL176774A0 (de)
MX (1) MXPA06008086A (de)
NO (3) NO336916B1 (de)
NZ (1) NZ548454A (de)
PL (1) PL1703896T3 (de)
PT (1) PT1703896E (de)
WO (1) WO2005067893A2 (de)
ZA (1) ZA200606310B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
MY171061A (en) * 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CN101678112B (zh) * 2007-01-19 2016-08-31 哈南亚有限公司 用于递送治疗剂的方法和组合物
CN101842079B (zh) 2007-08-31 2012-09-05 阿基米德开发有限公司 非水性药物组合物
US8507468B2 (en) * 2007-10-02 2013-08-13 Robert Orr Intranasal anti-convulsive compositions and methods
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
EP3090737A1 (de) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Kombinationstherapie mit peptidepoxyketonen
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (de) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Verbindungen zur immunproteasomhemmung
NZ602872A (en) 2010-04-07 2014-05-30 Onyx Therapeutics Inc Crystalline peptide epoxyketone immunoproteasome inhibitor
GB2481407B (en) * 2010-06-22 2012-05-23 Special Products Ltd A rapid onset liquid midazolam composition for buccal administration
CN102309438B (zh) * 2010-07-02 2013-04-17 中国人民解放军军事医学科学院毒物药物研究所 一种咪达唑仑药物组合物及其用途
CN102335430B (zh) * 2010-07-14 2013-07-31 中国人民解放军军事医学科学院毒物药物研究所 包含咪达唑仑与神经保护剂的复方药物组合物
CN102462685B (zh) * 2010-11-10 2014-07-30 中国人民解放军军事医学科学院毒物药物研究所 一种咪达唑仑组合物、其制备方法及用途
MY194947A (en) 2011-05-13 2022-12-27 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
ES2683902T3 (es) 2011-06-14 2018-09-28 Hale Biopharma Ventures, Llc Administración de benzodiacepina
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US20200297734A1 (en) * 2015-06-19 2020-09-24 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US11045462B2 (en) * 2016-06-14 2021-06-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods for treating neurological conditions and exposure to nerve agents
WO2019226753A1 (en) 2018-05-25 2019-11-28 Ucb Biopharma Sprl Benzodiazepine formulations
EP3897577A1 (de) 2018-12-18 2021-10-27 Cipla Limited Intranasale formulierung
US20210322343A1 (en) * 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders
JP2024521399A (ja) 2021-06-10 2024-05-31 ニューレリス、インク． 小児患者における発作性障害を治療するための組成物および方法
CN113209013B (zh) * 2021-06-24 2023-04-07 新疆特丰药业股份有限公司 一种咪达唑仑液体制剂及其制备方法和用途
NL2031331B1 (en) 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of a short-acting psychedelic compound
NL2031332B1 (en) 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of psychoactive compounds

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812853A (en) 1971-11-17 1974-05-28 P Crain Apparatus for applying medication or the like to human nasal passages
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US5132114A (en) 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
AU601176B2 (en) 1986-03-10 1990-09-06 Kurt Burghart Benzodiazepine aerosols
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
US4973596A (en) 1988-05-20 1990-11-27 Barr Laboratories, Inc. Method of administering a narcotic analgesic and dosage forms therefor
US4950664A (en) 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
US5776434A (en) 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
FR2662672B1 (fr) 1990-05-31 1992-08-21 Aerosols & Bouchage Dispensateur de melange.
US5166202A (en) * 1990-09-19 1992-11-24 Trustees Of The University Of Pennsylvania Method for the treatment of panic disorder
CA2111002C (en) 1991-06-10 2000-08-22 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
GB9125699D0 (en) 1991-12-03 1992-01-29 Glaxo Group Ltd Device
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
SK51695A3 (en) 1992-10-19 1995-11-08 Dura Pharma Inc Dry powder medicament inhaler
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
CA2152684A1 (en) * 1994-07-01 1996-01-02 Richard Anthony Henry Aerosol delivery of midazolam
US5529787A (en) 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
ATE223202T1 (de) 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
US5866143A (en) 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
US5622166A (en) 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US5948389A (en) 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5637314A (en) 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
WO1998002186A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Inclusion complex containing indole selective serotonin agonist
DE19709702A1 (de) 1997-03-10 1998-09-17 Wolff Walsrode Ag Lackbindemittelzubereitungen, deren Herstellung und Verwendung
US5855907A (en) 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
FR2772271B1 (fr) 1997-12-11 2000-09-01 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
EP1067942A1 (de) * 1998-02-23 2001-01-17 Cyclops, EHF. Hochenergetische cyclodextrinkomplexe
DE19807921A1 (de) 1998-02-25 1999-08-26 Pfeiffer Erich Gmbh & Co Kg Austrag-Steuerung für einen Medien-Spender
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2000074651A1 (de) 1999-06-02 2000-12-14 Hexal Ag Pharmazeutische zusammensetzung zur nasalen anwendung von wasserunlöslichen und/oder schwer wasserlöslichen wirkstoffen
US6627211B1 (en) 1999-07-26 2003-09-30 Sk Corporation Transnasal anticonvulsive compositions and modulated process
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU7937500A (en) 1999-10-27 2001-05-08 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040176359A1 (en) 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
CA2446060A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
ATE415155T1 (de) 2001-05-24 2008-12-15 Alexza Pharmaceuticals Inc Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation
GB0116107D0 (en) 2001-06-30 2001-08-22 West Pharm Serv Drug Res Ltd Pharmaceutical composition
GB0130964D0 (en) 2001-12-24 2002-02-13 Special Products Ltd Pharmaceutical composition
US20060039869A1 (en) 2004-08-17 2006-02-23 Daniel Wermeling Intranasal delivery of antipsychotic drugs

Also Published As

Publication number Publication date
NO336916B1 (no) 2015-11-23
US7700588B2 (en) 2010-04-20
CA2553890C (en) 2012-10-02
NZ548454A (en) 2010-05-28
FIC20230024I1 (fi) 2023-07-19
EA014096B1 (ru) 2010-08-30
ES2319667T3 (es) 2009-05-11
JP2007534660A (ja) 2007-11-29
GB0400804D0 (en) 2004-02-18
CN1929816B (zh) 2011-08-24
KR20060130175A (ko) 2006-12-18
PL1703896T3 (pl) 2009-06-30
PT1703896E (pt) 2009-02-25
NO20063453L (no) 2006-09-26
EP1703896B1 (de) 2008-12-17
WO2005067893A2 (en) 2005-07-28
AU2005205072A1 (en) 2005-07-28
EP1703896A2 (de) 2006-09-27
ZA200606310B (en) 2007-12-27
EA200601309A1 (ru) 2006-12-29
CN1929816A (zh) 2007-03-14
FIC20230023I1 (fi) 2023-07-11
WO2005067893A3 (en) 2006-04-13
NO2023014I1 (no) 2023-03-21
JP5085138B2 (ja) 2012-11-28
BRPI0506868A (pt) 2007-05-29
DE602005011753D1 (de) 2009-01-29
DK1703896T3 (da) 2009-03-02
IL176774A0 (en) 2006-10-31
NO2023011I1 (no) 2023-03-16
MXPA06008086A (es) 2006-12-19
AU2005205072B2 (en) 2011-03-03
US20060009447A1 (en) 2006-01-12
CA2553890A1 (en) 2005-07-28
US20050153956A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
FIC20230024I1 (fi) Farmaseuttisia koostumuksia, jotka käsittävät midatsolaamia suuressa pitoisuudessa
ES2567041T3 (es) Antagonista del receptor de angiotensina II para el tratamiento de diabetes mellitus en gatos
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
EA200701731A1 (ru) Аэрозольные и впрыскиваемые рецептуры лекарственных препаратов бензодиазепина, состоящего из наночастиц
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
NO20075111L (no) Farmasoytisk sammensetning
CY1116831T1 (el) ΧΡΗΣΗ 24-norUDCA
RU2010139958A (ru) Стабилизированная фармацевтическая композиция, cодержащая доцетаксель
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
RU2012154449A (ru) Катетер, допускающий различные дозировки активного агента
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
ECSP109871A (es) Soluciones farmacéuticas orales que contienen telbivudina
DE50312224D1 (de) Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel
MY160005A (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
ATE451385T1 (de) Verbindungen zur inhibierung von apoptose
WO2006121857A3 (en) Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses
TH128481A (th) 11-(2-ไพร์โรลิดิน-1-อิล-เอทอกซี)-14,19-ไดออกซา-5,7,26-ไตรอะซา-เตตราไซโคล [19.3.1.1(2,6).1(8,12)]เฮปทาโคซา-1(25),2(26),3,5,8,10,12(27),16,21,23-เดคาอีน ซิเตรท ซอลท์
TH83344B (th) ยาสำหรับรักษาหรือป้องกันโรคที่เกี่ยวกับการเกิดเนื้อเส้นใยอย่างผิดปกติ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1703896

Country of ref document: EP